A Phase 1, Open Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, or Non- Small Cell Lung Cancer
A study for patients with Melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell Lung cancer using study drug MGA271
Sponsor: Macrogenics
Enrolling: Male and Female Patients
IRB Number: AAAP4013
U.S. Govt. ID: NCT02475213
Contact: Richard Carvajal MD: 646-317-6344 / rdc2150@cumc.columbia.edu
Additional Study Information: The study involves research about MGA271 in combination with Keytruda. MGA271 targets cancer cells that make a lot of a protein called B7-H3. Another way to say it is that the cells "overexpress" the protein. Very few normal cells express B7-H3. MGA271 is though to work by recognizing cancer cells that overexpress B7-H3 and directing the body's immune system to kill those cells. Keytruda works in a different way. Some cancer cells hide from the immune system's attack by taking control of what is called the PD-1 pathway. Keytruda works by blocking the PD-1 pathway allowing the immune system to recognize and attack the expressing cancer cells. This combination of MGA271 and Keytruda may help the immune system to better recognize and destroy tumor cells. This study will be designed in two parts. The first part is designed to determine the best amount of the drug to be given. The second part is designed to use the dose that was determined in the first part and test the drug on a larger amount of individuals and see if the drug in combination with Keytruda can be effective as a treatment in breast cancer. For confirmed diagnosis of melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell lung cancer.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Do you have a confirmed diagnosis of melanoma, Squamous Cell Cancer of the Head and Neck or Non-Small Cell lung cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Richard Carvajal MD
rdc2150@cumc.columbia.edu
646-317-6344